Clinical trials: Gastrointestinal Reflux
Non Erosive Reflux Disease, Chronic Gastritis
Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients
To compare the symptom control rate between 8 weeks esomeprazole treatment regimen group and 2 weeks esomeprazole treatment regimen group in co-diagnosed NERD and chronic gastritis patients, as evaluated by GerdQ after 24 weeks…
- Trial name
- NCT01119768
- Testing
- Esomeprazole
- Where
- 8 sites in China
- Volunteers
- 305 people
- Sponsor
- AstraZeneca
Gastro Oesophageal Reflux Disease
Study Comparing Fexuprazan and Esomeprazole in Patients With Gastroesophageal Reflux Disease
The goal of this clinical trial was to evaluate the effectiveness and safety of fexuprazan 40 mg for relieving symptoms of gastroesophageal reflux disease (GERD) in adults.
- Trial name
- NCT07326904
- Testing
- Fexuprazan, Esomeprazole
- Where
- 3 sites in Indonesia
- Volunteers
- 145 people
- Sponsor
- Universitas Indonesia
Gastroesophageal Reflux Disease (GERD)
Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to compare the efficacy of rabeprazole extended release 50 mg (once daily) versus ranitidine 150 mg (twice daily) in the maintenance of complete healing in subjects with healed erosive…
- Trial name
- NCT00839306
- Testing
- Rabeprazole ER, Ranitidine
- Where
- 4 sites in United States
- Volunteers
- 240 people
- Sponsor
- Eisai Inc.
Gastroesophageal Reflux
Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy
The purpose of this study is to determine if patients with well-controlled heartburn symptoms on twice-daily proton pump inhibitor therapy remain well-controlled after stepping down to once-daily (QD) dexlansoprazole modified…
- Trial name
- NCT00847808
- Testing
- Dexlansoprazole MR QD
- Where
- 52 sites in United States
- Volunteers
- 178 people
- Sponsor
- Takeda
Gastroesophageal Reflux Disease
Efficacy of Pantoprazole 20/40 mg Once Daily (od) in Patients Older Than 12 Years Who Have Gastrointestinal Symptoms of Reflux Disease
The aim of this study was to evaluate the effect of 14 days treatment with Pantoprazole 40 mg and 20 mg on gastroesophageal reflux disease (GERD) related symptoms in a large patient population.
- Trial name
- PARADE (NCT00829738)
- Testing
- Pantoprazole
- Where
- 717 sites in Germany
- Volunteers
- 4,188 people
- Sponsor
- Nycomed
GERD
Correlates of GERD Symptom Severity
This is a pilot study measuring physiologic and behavioral correlates of symptom severity in adult patients with gastroesophageal reflux disease (GERD).
- Trial name
- NCT03020550
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Reflux
Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male Subjects
The purpose of this study is to investigate the pharmacodynamic effect of AZD2516 in healthy male subjects.
- Trial name
- NCT01154634
- Testing
- AZD2516, 5 mg, AZD2516, 16 mg, AZD2516, 40 mg
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease, Eosinophilic Esophagitis
The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors
Background: Up to 40% of patients who are treated with PPIs for symptoms that are thought to be due to GERD experience only incomplete relief of their symptoms.
- Trial name
- NCT01404832
- Testing
- Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Dallas VA Medical Center
Gastroesophageal Reflux, Asthma
Elucidation of Acid-Induced Pulmonary Inflammation
This study will evaluate how heartburn may lead to different types of inflammation in one's airways. Additionally, the study will determine whether aggressive treatment of heartburn results in improvement in both symptoms of…
- Trial name
- NCT00361972
- Testing
- lansoprazole
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Utah
Gastroesophageal Reflux
Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease
The purpose of this study is to assess the pharmacokinetics and safety of dexlansoprazole, once daily (QD), in pediatric subjects with symptomatic Gastroesophageal Reflux Disease.
- Trial name
- NCT01045096
- Testing
- Dexlansoprazole
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Takeda
Gastroesophageal Reflux Disease (GERD)
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to investigate the efficacy and safety of Rabeprazole (RAB) Extended-Release (ER) 50 mg versus Esomeprazole (ESO) 40 mg in subjects with erosive gastroesophageal reflux disease (eGERD).
- Trial name
- NCT00658632
- Testing
- Rabeprazole sodium, Esomeprazole
- Where
- 85 sites in United States
- Volunteers
- 1,397 people
- Sponsor
- Eisai Inc.
Gastroesophageal Reflux Disease (GERD)
Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD)…
- Trial name
- NCT03561883
- Testing
- IW-3718, Standard-dose PPIs QD
- Where
- 101 sites in United States, Canada
- Volunteers
- 609 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Reflux Episodes
TLESR-impedance Study in Patients
The purpose of the study is to compare frequency and content of reflux episodes in patients with gastroesophageal reflux disease.
- Trial name
- NCT00743444
- Testing
- AZD3355
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Esophagitis, Reflux, Esophagitis, Peptic
Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis
The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE).
- Trial name
- NCT00255151
- Testing
- Dexlansoprazole MR
- Where
- 100 sites in United States
- Volunteers
- 451 people
- Sponsor
- Takeda
Reflux Esophagitis, Gastric Ulcer
A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer
This is an open label, parallel group, multi-centre, phase III study to assess the safety and efficacy of D961H in maintenance therapy following initial healing therapy in Japanese paediatric patients with reflux esophagitis, and…
- Conditions
- Reflux Esophagitis, Gastric Ulcer, Duodenal Ulcer
- Trial name
- NCT03553563
- Testing
- D961H capsule 10mg, D961H sachet 10mg
- Where
- 15 sites in Japan
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Otitis Media With Effusion
A Clinical Trial of Proton Pump Inhibitors to Treat Children With Chronic Otitis Media With Effusion
This study is being done to see if reflux of stomach fluid might be a cause of chronic fluid in the ears. Our hypothesis is that treatment with an anti-reflux medication (lansoprazole) will increase the rate of resolution of…
- Trial name
- NCT00546117
- Testing
- lansoprazole
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Gastroesophageal Reflux
Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)
To evaluate the clinical outcomes of treatment with oral pantoprazole in children 1 through 5 years of age with endoscopically proven symptomatic GERD.
- Trial name
- NCT00300755
- Testing
- pantoprazole sodium enteric-coated spheroid
- Where
- 43 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Gastroesophageal Reflux Disease
A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience
The purpose of the study is to estimate what effect 4 different doses of AZD3355 will have on the number of reflux episodes, in patients who have GERD and still experience symptoms despite proton pump inhibitor (PPI) treatment.
- Trial name
- NCT01043185
- Testing
- AZD3355
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Sleep Disorders, Non-Erosive Reflux Disease
Pantoprazole 20/40 mg in the Treatment of Symptomatic Reflux Disease With Focus on Sleep Disorders
The aim of the study was to evaluate the effect of pantoprazole on sleep disorders in patients with NERD (non-erosive reflux disease) or eGERD (erosive gastroesophageal reflux disease).
- Conditions
- Sleep Disorders, Non-Erosive Reflux Disease, Gastroesophageal Reflux Disease
- Trial name
- PANDA (NCT00830115)
- Testing
- Pantoprazole
- Where
- 201 sites in Germany
- Volunteers
- 1,045 people
- Sponsor
- Nycomed
GERD, Acid Reflux Disease
Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms
This research study is being done to gather information about how to do further clinical studies using AZD3355 as an add-on treatment to proton pump inhibitors (PPI).
- Conditions
- GERD, Acid Reflux Disease, Heartburn, Regurgitation
- Trial name
- C27 (NCT00703534)
- Testing
- AZD3355, Gelusil®
- Where
- 84 sites in United States
- Volunteers
- 478 people
- Sponsor
- AstraZeneca